The cognitive efficacy of atypical antipsychotics in schizophrenia

Journal of Clinical Psychopharmacology

Volumn 18, Issue 2 SUPPL. 1, 1998, Pages

  Sharma, Tonmoy ^a   Mockler, Darren ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; SEROTONIN 2 RECEPTOR; THIORIDAZINE; ZOTEPINE;

ATTENTION; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; SCHIZOPHRENIA; VERBAL BEHAVIOR;

EID: 0031943635     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199804001-00004     Document Type: Conference Paper

References (87)

1. Stevens M, Crow TJ, Bowman MJ, Coles EC. Age disorientation in schizophrenia: a constant prevalence of 25 percent in a chronic mental hospital population? Br J Psychiatry 1978;133:130-6.
2. Liddle PF, Crow TJ. Age disorientation in chronic schizophrenia is associated with global intellectual impairment. Br J Psychiatry 1984;144:193-9.
3. Shallice T, Burgess PW, Frith CD. Can the neuropsychological case-study approach be applied to schizophrenia? Psychol Med 1991;21:661-73.
4. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, Gur RC. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994; 51:124-31.
5. Tamlyn D, McKenna PJ, Mortimer AM, Lund CE, Hammond S, Baddeley AD. Memory impairment in schizophrenia: its extent, affiliations and neuropsychological character. Psychol Med 1992; 22:101-15.
6. Laws RL, McKenna PJ, McCarthy RAM. Delusions about people. Neurocase 1995;1:349-62.
7. Laws RL, McKenna PJ, McCarthy RAM. Reconsidering, the gospel according to group studies: a neuropsychological case study approach to schizophrenia. Cogn Neuropsychiatry 1998 (in press).
8. Smith A. Mental deterioration in chronic schizophrenia. J Nerv Ment Dis 1964;139:479-87.
9. Klonoff H, Fibiger CH, Hutton GH. Neuropsychological patterns in schizophrenia. J Nerv Ment Dis 1970;150:291-300.
10. Waddington JL, Youssef HA, Kinsella A. Cognitive dysfunction in schizophrenia followed up over 5 years and its longitudinal relationship to the emergence of tardive dyskinesia. Psychol Med 1990;20:835-42.
11. Hoff AL, Riordan H, O'Donnell DW, Morris L, Delis LE. Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry 1992;149:898-903.
12. Heaton R, Paulsen JS, McAdams LA, Kuck J, Zisook S, Braff D, Harris J, Jeste DV. Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. Arch Gen Psychiatry 1994;51:469-76.
13. Hyde TM, Nawroz S, Goldberg TE, Bigelow LB, Strong D, Ostrem JL, Weinberger DR, Kleinman JE. Is there cognitive decline in schizophrenia? A cross-sectional study. Br J Psychiatry 1994;164: 494-500.
14. Mockler D, Riordan J, Sharma T. Memory and intellectual deficits do not decline with age in schizophrenia. Schizophr Res 1997; 26:1-7.
15. Ciompi L. Catamnestic long term study on the course and ageing of schizophrenics. Schizophr Bull 1981;6:606-18.
16. Nelson HE, Pantelis C, Carruthers K, Speller J, Baxendale S, Barnes TR. Cognitive functioning and symptomatology in chronic schizophrenia. Psychol Med 1990;29:357-65.
17. Sweeney JA, Haas GL, Li, S. Neuropsychological and eye movement abnormalities in first-episode and chronic schizophrenia. Schizophr Bull 1992;18:283-93.
18. Bilder RM, Lipschutz-Broch L, Reiter G, Geisler SH, Mayerhoff DI, Lieberman JA. Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophr Bull 1992; 18:437-48.
19. Myung AL, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994; 55[suppl B]:82-7.
20. Laws RL, McKenna PJ. Psychotic symptoms and cognitive deficits: what relationship? Neurocase 1997;3:41-9.
21. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-12.
22. Frith C. Functional imaging and cognitive abnormalities. Lancet 1995;346:615-20.
23. Dimasio A, Anderson SW. The frontal lobes. In: Helman KM, Valenstein E, eds. Clinical neuropsychology. New York: Oxford University Press 1993:409-60.
24. Nuechterlein KH, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull 1984;19:160-203.
25. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-30.
26. Jaeger J, Douglas E. Neuropsychiatric rehabilitation for persistent mental illness. Psychiatr Q 1992;63:71-94.
27. Delahunty A, Morice R, Frost B. Specific cognitive flexibility rehabilitation in schizophrenia. Psychol Med 1993;23:221-7.
28. Davidson M, Keefe RS. Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophr Res 1995;17: 123-9.
29. Sharma T. Schizophrenia: recent advances in psychopharmacology. Br J Hosp Med 1996;55:194-8.
30. Nuechterlein KH. Signal detection in vigilance tasks and behavioral attributes among offspring of schizophrenic mothers and among hyperactive children. J Abnorm Psychol 1983;92:4-28.
31. Schreiber H, Stolz Born G, Kornhuber HH, Born J. Event-related potential correlates of impaired selective attention in children at high risk for schizophrenia. Biol Psychiatry 1992;32:634-51.
32. Roxborough H, Muir WJ, Blackwood DHR, Walker MT, Blackburn IM. Neuropsychological and P300 abnormalities in schizophrenics and their relatives. Psychol Med 1993;23:305-14.
33. Sharma T. Structural and functional endophenotypes in schizophrenia. In: Kerwin R, ed. Neurobiology and psychiatry. Cambridge: Cambridge University Press, 1995:3:25-32.
34. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatr Clin North Am 1993;16:295-312.
35. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993;162:43-8.
36. Kenny JT, Meltzer HY. Attention and higher cortical functions in schizophrenia. J Neuropsychiatry Clin Neurosci 1991;3:269-75.
37. Oltmanns TF, Neale JM. Schizophrenic performance when distractors are present: attentional deficit or differential task difficulty? J Abnorm Psychol 1975;84:205-9.
38. Kremen WS, Tsuang MT, Faraone SV, Lyons MJ. Using vulnerability indicators to compare conceptual models of genetic heterogeneity in schizophrenia. J Nerv Ment Dis 1992;180:141-52.
39. Gold JM, Randolph C, Carpenter CJ, Goldberg TE, Weinberger DR. Forms of memory failure in schizophrenia. J Abnorm Psychol 1992;101:487-494.
40. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley CH, Resnick SM, Kester DM, Stafiniak P. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 1991;48:612-24.
41. Cohen JD, Servan-Schreiber D. Context, cortex, and dopamine: a connectionist approach to behavior and biology in schizophrenia. Psychol Rev 1992;99:45-77.
42. Sullivan EV, Mathalon DH, Ha CN, Zipursky RD, Pfefferbaum A. The contribution of constructional accuracy and organizational strategy to nonverbal recall in schizophrenia and chronic alcoholism. Biol Psychiatry 1992;32:312-33.
43. Keefe RS, Roitman SE, Harvey PD, Blum CS, Dupre RL, Prieto DM, Davidson M, Davis KL. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophr Res 1995;7:25-33.
44. Morice R. Cognitive inflexibility and pre-frontal dysfunction in schizophrenia and mania. Br J Psychiatry 1990;157:50-4.
45. Andreasen NC, Rezai K, Alliger R, Swayze VW, Flaum M, Kirchner P, Cohen G, O'Leary DS. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 1992;49:943-58.
46. King DJ. The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry 1990;157:799-811.
47. Kornetsky C, Mirsky AF. On certain psychopharmacological and physiological differences between schizophrenic and normal persons. Psychopharmacologia 1966;8:309-18.
48. Mirsky AF, Primac DW, Bates R. The effects of chlorpromazine and secoarbital on the continuous performance test. J Nerv Ment Dis 1959;128:12-7.
49. Hartley LR. Arousal, temporal and spatial uncertainty and drug effects. Prog Neuropsychopharmacol Biol Psychiatry 1983;7:29-37.
50. Dimascio A, Havens LL, Klerman GL. The psychopharmacology of phenothiazine compounds: a comparative study of the effects of chlorpromazine, promethazine, trifluoperazine and perphenazine in normal males. Introduction, aims and methods. J Nerv Ment Dis 1963;136:15-28.
51. Liljequist R, Linnoila M, Mattila MJ. Effects of two weeks treatment with thioridazine, chlorpromazine, sulpiride and bromaze-pam, alone or in combination with alcohol, on learning and memory in man. Psychopharmacologia 1978;55:205-8.
52. Cassens G, Inglis AK, Applebaum PS, Gutheil TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990;16:477-99.
53. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 1989;98:367-80.
54. King DJ. Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiatr Scand 1994;38[suppl]:53-8.
55. Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM. Neuroleptic drug effects on cognitive function in schizophrenia. Schizophr Res 1990;3:11-9.
56. Bilder RM, Turkel E, Lipschutz-Broch L, Lieberman JA. Antipsychotic medication effects on neuropsychological functions. Psychopharmacol Bull 1992;28:353-66.
57. Berman KF, Zee RF, Weinberger DR. Physiologic dysfunction of dorsolateral prefrontal cortexin schizophrenia. II. Role of neuroleptic treatment, attention and mental effort. Arch Gen Psychiatry 1986;43:126-35.
58. Medallia A, Gold J, Merriam A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychology 1988;3:249-71.
59. Classen W, Laux G. Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol or clozapine. Pharmacopsychiatry 1988;21:295-7.
60. Sweeney JA, Keilp JG, Haas GL, Hill J, Weiden PJ. Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Res 1991;37:297-308.
61. Tune LE, Strauss ME, Lew MF, Breitlinger E, Coyle JT. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 1982;139:1460-2.
62. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
63. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992;160[suppl]:46-53.
64. Saletu B, Grunberger J, Linzmayer L, Anderer P. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing phamaco-EEG and psychometry. Pharmacopsychiatry 1987;20:12-27.
65. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36:717-25.
66. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994;55[suppl B]:82-7.
67. Hoff AL, Faustman WO, Wieneke M, Espinoza S, Coita M, Wolkowitz O, Csernansky JG. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 1996;15:361-9.
68. Fujii DEM, Ahmed I, Jokumsen M, Compton JM. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. J Neuropsychiatry Clin Neurosciences 1997;9: 240-5.
69. Gallhofer B, Bauer U, Gruppe H, Krieger S, Lis S. First episode schizophrenia: the importance of compliance and preserving cognitive function. J Pract Psychiatry Behav Health 1966;2:S16-S24.
70. Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 1996;41[suppl 2]:S35-S40.
71. Green MF, Marshall BD, Wirshing MD, Ames D, Marder SR, McGurk S, Kern RS, Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804.
72. Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, Casacchia M. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 1997;95:40-3.
73. Daniel DG. Comparison of risperidone and clozapine on clinical cognitive functions in psychotic disorders [abstract]. Biol Psychiatry 1994;35:667.
74. Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996;6[suppl 2]:S13-S20.
75. Benton AL, Hamsher K des, eds. Multilingual aphasia examination. Iowa City: University of Iowa, 1978.
76. Benton AL, Hamsher K des, Varney NR, Spreen O. Contributions to neuropsychological assessment. New York: Open University Press, 1983.
77. Wechsler D. WAIS-R. New York: Psychological Corporation, 1981.
78. Smith A. Symbol digit modalities test: manual. Los Angeles: Western Psychological Services, 1973.
79. Reitan RM. Manual for administration of neuropsychological test batteries for adults and children. Tucson: Reitan Neuropsychological Laboratory, 1979.
80. Benton AL. Revised visual retention test: clinical and experimental applications. 4th ed. San Antonio: Psychological Corporation, 1974.
81. Heaton R. Wisconsin card sorting manual. Odessa, FL: Psychological Assessment Resources, 1981.
82. Goldberg TE, Weinberger DR. The effects of clozapine on neurocognition: an overview. J Clin Psychiatry 1994;55[suppl B]:88-90.
83. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-10.
84. Farde L, Nordstrom A. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 1992[suppl];30-3.
85. Meltzer HY. The mechanism of action of novel atypic antipsychotic drugs. Schizophr Bull 1991;17:263-87.
86. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
87. Harvey PD, Lombardi J, Leibman M, White L, Parrella M, Powchik P, Davidson M. Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study. Schizophr Res 1996;22:223-31.